Drug
Tocilizumab Roactemra Actemra
Tocilizumab Roactemra Actemra: highest development phase Phase 3, developed by Roche. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Roche
Trials
| Drug | Phase | Indication |
|---|---|---|
| tocilizumab [RoActemra/Actemra] NCT01326962 | Phase 3 | Rheumatoid Arthritis |
Latest
No recent events.
Follow Tocilizumab Roactemra Actemra on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.